JP2007530525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530525A5 JP2007530525A5 JP2007504496A JP2007504496A JP2007530525A5 JP 2007530525 A5 JP2007530525 A5 JP 2007530525A5 JP 2007504496 A JP2007504496 A JP 2007504496A JP 2007504496 A JP2007504496 A JP 2007504496A JP 2007530525 A5 JP2007530525 A5 JP 2007530525A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- cycloalkyl
- independently
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55562304P | 2004-03-23 | 2004-03-23 | |
| US60/555,623 | 2004-03-23 | ||
| PCT/IB2005/000659 WO2005092864A1 (en) | 2004-03-23 | 2005-03-11 | Imidazole compounds for the treatment of neurodegenerative disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007156459A Division JP2007291123A (ja) | 2004-03-23 | 2007-06-13 | 神経変性障害の治療のためのイミダゾール化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007530525A JP2007530525A (ja) | 2007-11-01 |
| JP2007530525A5 true JP2007530525A5 (https=) | 2007-12-13 |
| JP4054845B2 JP4054845B2 (ja) | 2008-03-05 |
Family
ID=34961257
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007504496A Expired - Lifetime JP4054845B2 (ja) | 2004-03-23 | 2005-03-11 | 神経変性障害の治療のためのイミダゾール化合物 |
| JP2007156459A Pending JP2007291123A (ja) | 2004-03-23 | 2007-06-13 | 神経変性障害の治療のためのイミダゾール化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007156459A Pending JP2007291123A (ja) | 2004-03-23 | 2007-06-13 | 神経変性障害の治療のためのイミダゾール化合物 |
Country Status (42)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1934091B (zh) | 2004-03-23 | 2012-02-08 | 辉瑞产品公司 | 治疗神经变性障碍的咪唑化合物 |
| WO2007034326A2 (en) * | 2005-09-22 | 2007-03-29 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurological disorders |
| MY149143A (en) | 2006-01-18 | 2013-07-15 | Amgen Inc | Thiazole compounds as protien kinase b (pkb) inhibitors |
| DE102006048042A1 (de) * | 2006-10-11 | 2008-04-17 | Bayer Healthcare Ag | Acylaminoimidazole und Acylaminothiazole |
| EP2205072B1 (en) * | 2007-10-15 | 2013-11-20 | The Salk Institute for Biological Studies | Methods for treating a variety of diseases and conditions, and compounds useful therefor |
| WO2009093463A1 (ja) * | 2008-01-23 | 2009-07-30 | Taiho Pharmaceutical Co., Ltd. | 神経細胞死抑制剤 |
| WO2010096371A2 (en) | 2009-02-18 | 2010-08-26 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds which modulate the cb2 receptor |
| US20120053165A1 (en) * | 2009-03-03 | 2012-03-01 | Pfizer Inc. | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators |
| US8299103B2 (en) * | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| US9315454B2 (en) | 2010-01-15 | 2016-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| JP5746764B2 (ja) | 2010-07-22 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| RU2465273C2 (ru) * | 2010-08-31 | 2012-10-27 | Общество С Ограниченной Ответственностью "Биофарм-Меморейн" | ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| AU2012321345B2 (en) | 2011-10-03 | 2016-03-17 | The University Of Utah Research Foundation | Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| WO2015092614A1 (en) | 2013-12-20 | 2015-06-25 | Pfizer Inc. | Activating notch alterations in breast cancer |
| MX368391B (es) | 2015-02-03 | 2019-09-30 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas. |
| CN107922386B (zh) | 2015-06-22 | 2021-04-02 | 大日本住友制药株式会社 | 1,4-二取代的咪唑衍生物 |
| SG11201710694YA (en) | 2015-06-22 | 2018-01-30 | Sumitomo Dainippon Pharma Co Ltd | Bicyclic heterocyclic amide derivative |
| US10898469B2 (en) | 2016-02-26 | 2021-01-26 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazolylamide derivative |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| EP3843735A1 (en) * | 2018-08-27 | 2021-07-07 | Universiteit Maastricht | Selective presenilin-2 gamma-secretase inhibitors |
| KR20220024729A (ko) | 2019-06-24 | 2022-03-03 | 노파르티스 아게 | B-세포 성숙 항원을 표적으로 하는 다중특이성 항체에 대한 투여 요법 및 병용 요법 |
| KR20250030524A (ko) | 2019-08-09 | 2025-03-05 | 화이자 인코포레이티드 | (s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의고체 상태 형태 및 이의 용도 |
| US11884634B2 (en) | 2019-08-09 | 2024-01-30 | Pfizer Inc. | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
| EP4010322B1 (en) * | 2019-08-09 | 2025-11-05 | Pfizer Inc. | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof |
| KR102782229B1 (ko) * | 2019-10-02 | 2025-03-20 | (주)카이노스메드 | N-(1h-이미다졸-2-일)벤즈아미드 화합물 및 활성 성분으로 이를 포함하는 약학 조성물 |
| CA3182887A1 (en) | 2020-05-13 | 2021-11-18 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
| WO2022053990A1 (en) | 2020-09-14 | 2022-03-17 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| EP4255409A1 (en) | 2020-12-07 | 2023-10-11 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| US20240269120A1 (en) | 2021-06-02 | 2024-08-15 | Cellestia Biotech Ag | Method for Treating an Autoimmune and Inflammatory Disease |
| CA3230245A1 (en) * | 2021-09-01 | 2023-03-09 | Springworks Therapeutics, Inc. | Synthesis of nirogacestat |
| US11504354B1 (en) | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
| WO2023079132A1 (en) | 2021-11-08 | 2023-05-11 | Cellestia Biotech Ag | Pharmaceutical combinations for treating cancer |
| CN118302412A (zh) * | 2021-11-23 | 2024-07-05 | 梯瓦制药国际有限责任公司 | Nirogacestat盐的固态形式 |
| EP4223292A1 (en) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| WO2023174390A1 (zh) * | 2022-03-17 | 2023-09-21 | 苏州科睿思制药有限公司 | 尼罗司他二氢溴酸盐的晶型及其制备方法和用途 |
| US12138246B2 (en) | 2022-05-20 | 2024-11-12 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| IL316750A (en) | 2022-05-20 | 2025-01-01 | Springworks Therapeutics Inc | Treatments with Nirogesstat |
| US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| WO2026018210A1 (en) | 2024-07-19 | 2026-01-22 | Assia Chemical Industries Ltd. | Solid state forms of nirogacestat dihydrochloride salt |
| CN119930523B (zh) * | 2025-01-22 | 2026-01-02 | 上海皓元医药股份有限公司 | 一种硝加司他中间体的制备方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US50314A (en) * | 1865-10-03 | Improvement in telegraph-cables | ||
| US4512A (en) * | 1846-05-09 | Smut-machine | ||
| DE1236426B (de) * | 1960-08-25 | 1967-03-09 | Dolomitwerke Gmbh | Verfahren zur Wasseraufbereitung |
| US5401851A (en) | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| JPH07101958A (ja) | 1992-10-16 | 1995-04-18 | Takeda Chem Ind Ltd | セフェム化合物、その製造法および抗菌組成物 |
| DE19629816A1 (de) | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| ZA987385B (en) | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
| US6329342B1 (en) | 1997-08-19 | 2001-12-11 | Eli Lilly And Company | Treatment of congestive heart failure with growth hormone secretagogues |
| ZA987383B (en) | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
| US6639076B1 (en) | 1998-08-18 | 2003-10-28 | Eli Lilly And Company | Growth hormone secretagogues |
| US6828331B1 (en) | 1999-02-19 | 2004-12-07 | Eli Lilly And Company | Growth hormone secretagogues |
| CO5160260A1 (es) * | 1999-02-19 | 2002-05-30 | Lilly Co Eli | Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| DE10019755A1 (de) | 2000-04-20 | 2001-11-08 | Bayer Ag | Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten |
| EP1289526A4 (en) | 2000-05-30 | 2005-03-16 | Merck & Co Inc | MELANOCORTIN RECEPTOR AGONISTS |
| PY0117895A (es) * | 2000-07-31 | 2003-11-03 | Pfizer Prod Inc | Derivados de imidazol |
| JP2002059707A (ja) * | 2000-08-23 | 2002-02-26 | Bridgestone Corp | 空気入りタイヤ及び空気入りタイヤの製造方法 |
| JP2004513935A (ja) | 2000-11-17 | 2004-05-13 | ノボ ノルディスク アクティーゼルスカブ | グルカゴンアンタゴニスト／逆アゴニスト |
| TW200301698A (en) | 2001-12-21 | 2003-07-16 | Bristol Myers Squibb Co | Acridone inhibitors of IMPDH enzyme |
| WO2003055482A1 (en) | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Amide derivatives as gk activators |
| BRPI0311812B8 (pt) | 2002-06-05 | 2021-05-25 | Bristol Myers Squibb Co | antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso |
| WO2004033434A1 (en) | 2002-10-09 | 2004-04-22 | Pfizer Products Inc. | Pyrazole compounds for treatment of neurodegenerative disorders |
| KR20050070046A (ko) | 2002-10-09 | 2005-07-05 | 화이자 프로덕츠 인크. | 퇴행성신경 장애 치료를 위한 티아졸 화합물 |
| JP2006182648A (ja) * | 2003-04-08 | 2006-07-13 | Dai Ichi Seiyaku Co Ltd | ７員複素環誘導体 |
| BRPI0409721A (pt) | 2003-05-12 | 2006-05-02 | Pfizer Prod Inc | compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos |
| CA2533554A1 (en) | 2003-08-01 | 2005-02-10 | Pfizer Products Inc. | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders |
| MXPA06001480A (es) | 2003-08-06 | 2006-05-15 | Pfizer Prod Inc | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos. |
| JP2007502828A (ja) | 2003-08-21 | 2007-02-15 | ファイザー・プロダクツ・インク | 神経変性性疾患の治療のための化合物 |
| US7348968B2 (en) * | 2003-12-02 | 2008-03-25 | Sony Corporation | Wireless force feedback input device |
| GB0329275D0 (en) | 2003-12-18 | 2004-01-21 | Merck Sharp & Dohme | Therapeutic treatment |
| CN1934091B (zh) | 2004-03-23 | 2012-02-08 | 辉瑞产品公司 | 治疗神经变性障碍的咪唑化合物 |
| US7384968B2 (en) | 2004-04-01 | 2008-06-10 | Pfizer Inc. | Thiazole-amine compounds for the treatment of neurodegenerative disorders |
| US7232820B2 (en) | 2004-04-01 | 2007-06-19 | Pfizer Inc | Thiadiazole-amine compounds for the treatment of neurodegenerative disorders |
| US7163942B2 (en) | 2004-04-01 | 2007-01-16 | Pfizer Inc. | Sulfonamide compounds for the treatment of neurodegenerative disorders |
| US7220865B2 (en) | 2004-04-01 | 2007-05-22 | Pfizer Inc | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders |
| US7309709B2 (en) | 2004-04-01 | 2007-12-18 | Pfizer Inc. | Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders |
| US20050222227A1 (en) | 2004-04-01 | 2005-10-06 | Pfizer Inc | Oxazole-amine compounds for the treatment of neurodegenerative disorders |
| WO2007034326A2 (en) * | 2005-09-22 | 2007-03-29 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurological disorders |
-
2005
- 2005-03-11 CN CN2005800093217A patent/CN1934091B/zh not_active Expired - Lifetime
- 2005-03-11 PL PL05708746T patent/PL1730119T3/pl unknown
- 2005-03-11 SI SI200530339T patent/SI1730119T1/sl unknown
- 2005-03-11 AU AU2005225635A patent/AU2005225635B2/en not_active Expired
- 2005-03-11 CA CA002560580A patent/CA2560580C/en not_active Expired - Lifetime
- 2005-03-11 DE DE602005007717T patent/DE602005007717D1/de not_active Expired - Lifetime
- 2005-03-11 JP JP2007504496A patent/JP4054845B2/ja not_active Expired - Lifetime
- 2005-03-11 KR KR1020067019625A patent/KR100814599B1/ko not_active Expired - Lifetime
- 2005-03-11 ES ES05708746T patent/ES2308441T3/es not_active Expired - Lifetime
- 2005-03-11 BR BRPI0509069A patent/BRPI0509069B8/pt not_active IP Right Cessation
- 2005-03-11 AP AP2006003727A patent/AP2379A/xx active
- 2005-03-11 GE GEAP20059630A patent/GEP20084420B/en unknown
- 2005-03-11 HR HR20080375T patent/HRP20080375T3/xx unknown
- 2005-03-11 PT PT05708746T patent/PT1730119E/pt unknown
- 2005-03-11 EA EA200601494A patent/EA011689B1/ru not_active IP Right Cessation
- 2005-03-11 WO PCT/IB2005/000659 patent/WO2005092864A1/en not_active Ceased
- 2005-03-11 US US11/078,898 patent/US7342118B2/en not_active Expired - Lifetime
- 2005-03-11 EP EP05708746A patent/EP1730119B1/en not_active Expired - Lifetime
- 2005-03-11 DK DK05708746T patent/DK1730119T3/da active
- 2005-03-11 AT AT05708746T patent/ATE399155T1/de active
- 2005-03-11 UA UAA200610159A patent/UA83899C2/uk unknown
- 2005-03-11 RS RSP-2008/0351A patent/RS50595B/sr unknown
- 2005-03-11 NZ NZ549331A patent/NZ549331A/en not_active IP Right Cessation
- 2005-03-18 SV SV2005002055A patent/SV2006002055A/es unknown
- 2005-03-18 PE PE2005000313A patent/PE20051155A1/es not_active Application Discontinuation
- 2005-03-18 TW TW094108466A patent/TWI372146B/zh not_active IP Right Cessation
- 2005-03-18 HN HN2005000115A patent/HN2005000115A/es unknown
- 2005-03-21 GT GT200500060A patent/GT200500060A/es unknown
- 2005-03-21 DO DO2005000040A patent/DOP2005000040A/es unknown
- 2005-03-22 UY UY28817A patent/UY28817A1/es not_active Application Discontinuation
- 2005-03-22 AR ARP050101116A patent/AR049875A1/es not_active Application Discontinuation
- 2005-03-22 NL NL1028598A patent/NL1028598C2/nl not_active IP Right Cessation
- 2005-03-23 PA PA20058627201A patent/PA8627201A1/es unknown
-
2006
- 2006-08-21 IL IL177594A patent/IL177594A0/en active IP Right Grant
- 2006-08-21 ZA ZA2006/06957A patent/ZA200606957B/en unknown
- 2006-09-21 CR CR8644A patent/CR8644A/es unknown
- 2006-09-22 TN TNP2006000300A patent/TNSN06300A1/fr unknown
- 2006-09-22 EC EC2006006879A patent/ECSP066879A/es unknown
- 2006-09-22 MA MA29336A patent/MA28481B1/fr unknown
- 2006-10-09 IS IS8550A patent/IS8550A/is unknown
- 2006-10-18 NO NO20064726A patent/NO338263B1/no unknown
-
2007
- 2007-06-13 JP JP2007156459A patent/JP2007291123A/ja active Pending
-
2008
- 2008-01-09 US US11/971,272 patent/US7795447B2/en active Active
- 2008-09-17 CY CY20081101001T patent/CY1108347T1/el unknown
-
2010
- 2010-03-12 US US12/723,204 patent/US7951958B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007530525A5 (https=) | ||
| JP2009515872A5 (https=) | ||
| JP2002543183A5 (https=) | ||
| JP2007518682A5 (https=) | ||
| JP2008526724A5 (https=) | ||
| JP2011508726A5 (https=) | ||
| JP2005053931A5 (https=) | ||
| CY1109493T1 (el) | Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις | |
| JP2012500805A5 (https=) | ||
| JP2006524222A5 (https=) | ||
| JP2005514398A5 (https=) | ||
| JP2009502963A5 (https=) | ||
| JP2007508359A5 (https=) | ||
| JP2006522035A5 (https=) | ||
| JP2009526868A5 (https=) | ||
| ATE471323T1 (de) | Purinderivate als antagonisten an purinergen rezeptoren | |
| JP2006520397A5 (https=) | ||
| JP2006507355A5 (https=) | ||
| JP2001517655A5 (https=) | ||
| JP2010532365A5 (https=) | ||
| JP2004530691A5 (https=) | ||
| JP2004535380A5 (https=) | ||
| JP2001524477A5 (https=) | ||
| DE602004020730D1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen | |
| JP2017513852A5 (https=) |